These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26365572)

  • 1. Drug therapy for overactive bladder.
    Izett M; Zacchè M; Giarenis I; Robinson D; Cardozo L
    Minerva Ginecol; 2015 Dec; 67(6):557-74. PubMed ID: 26365572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current evidence and emerging drug therapies for overactive bladder.
    Izett M; Zacche M; Thiagamoorthy G; Robinson D; Cardozo L
    Minerva Ginecol; 2017 Jun; 69(3):269-285. PubMed ID: 28293939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.
    Zacche MM; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1365-74. PubMed ID: 24899225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging drugs for overactive bladder.
    Karmarkar R; Khullar V
    Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
    Thiagamoorthy G; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standard pharmacological treatment and new therapies for overactive bladder].
    Del Popolo G; Mencarini M; Li Marzi V
    Urologia; 2012; 79(1):6-13. PubMed ID: 22344568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the pharmacologic management of overactive bladder: the present and the future.
    Ellsworth P; Kirshenbaum E
    Urol Nurs; 2010; 30(1):29-38, 53. PubMed ID: 20359143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overactive bladder: strategies to ensure treatment compliance and adherence.
    Dhaliwal P; Wagg A
    Clin Interv Aging; 2016; 11():755-60. PubMed ID: 27350744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging investigational medical therapies for the treatment of overactive bladder.
    Tiwari A; Naruganahalli KS
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1017-37. PubMed ID: 16916270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.
    Kosilov KV; Loparev SA; Kuzina IG; Geltser BI; Shakirova OV; Zhuravskaya NS; Lobodenko A
    Investig Clin Urol; 2017 Mar; 58(2):109-116. PubMed ID: 28261680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The medical management of refractory overactive bladder.
    Robinson D; Giarenis I; Cardozo L
    Maturitas; 2013 Apr; 74(4):386-90. PubMed ID: 23395402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.
    Wagg AS
    Drugs Aging; 2012 Jul; 29(7):539-48. PubMed ID: 22715861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
    Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
    Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.